Contagion Live highlights the new publication in Infectious Diseases and Therapy showing data on the dual action of ILP100

Contagion Live highlights the new publication in Infectious Diseases and Therapy showing data on the dual action of ILP100 - healing of skin and mucosal surfaces AND killing Multi- and Severely Drug Resistant bacterial pathogens isolated in Ukraine, currently spreading across Europe and globally. "Elimination of MDR bacteria by the addition of ILP100 shows that antagonistic bacteria may provide promising new treatment options in the face of the currently stagnating antimicrobial pipeline," Professor Mia Phillipson concludes.

  BEAM Alliance shares news of data of ILP100 killing multi drug resistant bacteria

Link to open source publication in Infectious Diseases and Therapy: https://link.springer.com/article/10.1007/s40121-025-01137-y

  Ilya Pharma CEO selected for Eisenhower Fellowship named after American President Dwight D. Eisenhower to promote global peace and development

The topic of the Fellowship centers on exploring the ongoing initiatives in Multi-Drug Resistant (MDR) pathogen testing, treatment and policy reform with the aim to participate to the #solution identifying and collaborating with stakeholders and discover how the companys resent research in fighting MDR microbes with therapeutic microbes in different diseases may best deliver impact to patients.

  Mia Phillipson and Evelina Vågesjö receives Hans Wigzells Research Foundations Scientific price of 100 000 USD

  Developments of ILP100-Oral was highlighted in an Editorial by American Journal of Gastrointestinal and Liver Physiology

"The implications of this study are substantial, extending beyond immediate therapeutic benefits to broader impacts on the field of colitis treatment and potentially other inflammatory diseases. The methodology used in this study could be adapted for other inflammatory diseases by engineering L. reuteri to express different therapeutic proteins. This broadens the potential applications of this approach beyond colitis" Our asset ILP100-Oral is currently at IND stage in development with: ✅ FDA pre-IND meeting completed allowing first-line-treatment ✅ SITU-GUT clinical phase 1/2a trial developed with KOLs for ICI-induced colitis stage 1 and 2 ✅CMC and GMP synergies with ILP100-Topical already in Phase 2 clinical developments with IND cleared for pivotal study ✅ Exceptional COGs, stability in room temperature ✅ Projections of blockbuster potential ➡️ The company seeking a suitable partner to accelerate the clinical development for this asset and share the expected joys of developing ground breaking research 💊 and the expected value generated💰 💰

  Schweizeraktien.net shares SIX Sparks IPO Academy Kick off event

  Ilya Pharma Receives Rare Pediatric Disease Designation From US FDA

  Nordic Life Science reports on Ilya Pharmas 5 mEUR financing round

  American Physiological Society selects the publication by Öhnstedt et al 2024 describing the MOA and preclinical PoC for ILP100-Oral as a APSselect publication

American Journal of Physiology-Gastrointestinal and Liver Physiology, June 2024 issue Title: Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models Authors: Emelie Öhnstedt, Cristian Doñas, Kristel Parv, Yanhong Pang, Hava Lofton Tomenius, Macarena Carrasco López, Venkata Ram Gannavarapu, Jacueline Choi, Maria Ovezik, Peter Frank, Margareth Jorvid, Stefan Roos, Evelina Vågesjö, and Mia Phillipson

  Ilya Pharma CEO in interviewed by LifeScience Sweden